Last Updated on: 22nd November 2023, 07:11 am
The International Waldenstrom’s Macroglobulinemia Foundation (IWMF) and Scientific Education Support (SES) have joined forces to launch new Waldenstrom’s Macroglobulinemia (WM) resources on the Lymphoma Hub, as part of the WM Awareness-Building Initiative.
The goal of this initiative is to provide healthcare professionals with the necessary information to make informed treatment decisions and to ensure that patients have access to the latest support and treatment options.
The new content includes a visual abstract on a phase I/II trial of pirtobrutinib in patients with R/R WM (BRUIN trial) and an article on the treatment landscape for relapsed/refractory WM. Additionally, the IWMF’s “Talking with your WM patients” resource is now available on the Lymphoma Hub, with a visual summary of this guide.
The IWMF and Lymphoma Hub are collaborating to raise awareness of WM among healthcare professionals, patients, caregivers, and the patient advocacy community. This initiative is funded by Cellectar Biosciences; however, all content is developed independently by SES in collaboration with an expert steering committee, and the funder has no influence on the content.
On Tuesday 6 June, 2023, the International Waldenstrom’s Macroglobulinemia Foundation (IWMF) and Scientific Education Support (SES) announced the launch of new resources for Waldenstrom’s Macroglobulinemia (WM) on the Lymphoma Hub, as part of the WM Awareness-Building Initiative.
The resources, which include a visual abstract on a phase I/II trial of pirtobrutinib in patients with R/R WM (BRUIN trial) and an article on the treatment landscape for relapsed/refractory WM, as well as the IWMF’s “Talking with your WM patients” guide and a visual summary, are designed to support healthcare professionals in making informed treatment decisions and to ensure that patients have access to the latest support and treatment options.
The IWMF and Lymphoma Hub are working together to raise awareness of WM among healthcare professionals, patients, caregivers, and the patient advocacy community. This initiative is funded by Cellectar Biosciences; however, all content is developed independently by SES in collaboration with an expert steering committee, and the funder has no influence on the content.
